research Prolonged treatment with finasteride (a 5α-reductase inhibitor) does not affect bone density and metabolism
Long-term finasteride use doesn't change bone density or metabolism.
Search
for
Sort by
Research
390-420 / 1000+ results 
research Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome
Rituximab leads to longer remission and fewer side effects than cyclophosphamide.
research Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
research Ion pairs of risedronate for transdermal delivery and enhanced permeation rate on hairless mouse skin
Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.
research Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis
Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
research Mining and analysis of adverse event signals of isotretinoin based on the real-world data of FAERS database
Isotretinoin has many serious side effects, including some new ones, needing better safety measures and updated labels.
research Finasteride-induced depression: new insights into possible pathomechanisms
Finasteride may increase depression by reducing brain cell growth.
research Brimonidine Beyond a Single Specialty: Pharmacological Profile, Dermatologic Applications, and Advances in Drug Delivery Systems
Brimonidine is effective for reducing facial redness in skin conditions and has potential for broader dermatological uses.
research 5 alpha-reductase inhibition by a new synthetic steroid (PM-9) in cultures of Penicillium crustosum.
PM-9, like finasteride, may help treat certain diseases by blocking a key enzyme.
research Finasteride: risk of suicidality and depression
Finasteride may increase the risk of depression and suicidal thoughts.
research The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
research Tratamiento de la Depresión durante el embarazo: perspectivas clínicas
SRD5A2 enzyme expression varies in benign prostates and can be influenced by inflammation, affecting treatment options.
research Testosterone Improves Antidepressant‐Emergent Loss of Libido in Women: Findings from a Randomized, Double‐Blind, Placebo‐Controlled Trial
Testosterone may help increase sexual events for women with low libido due to antidepressants.
research Isotretinoin treatment of acne and related disorders: An update
Isotretinoin effectively treats severe acne and similar conditions, but has common, mostly reversible side effects, requiring careful patient monitoring.
research Risk:benefit ratio in the treatment of psoriasis with systemic retinoids
Systemic retinoids are effective for psoriasis but have side effects; benefits may outweigh risks, especially when reducing cancer risks from other treatments.
research Molecular docking studies and ADME-Tox prediction of phytocompounds from Merremia peltata as a potential anti-alopecia treatment
The compound 16 from the Merremia peltata plant could potentially be a good treatment for hair loss (alopecia) due to its strong activity and favorable skin absorption.
research Ethinylestradiol/Chlormadinone Acetate
The oral contraceptive ethinylestradiol/chlormadinone acetate is effective in reducing acne and improving other skin conditions related to high androgen levels.
research 1424 METHYLATION AND DECREASED EXPRESSION OF 5-ALPHA REDUCTASE 2 IN HUMAN PROSATE SAMPLES: IMPLICATIONS FOR RESISTANCE TO THERAPY FOR BPH
Methylation of the 5-AR2 gene may cause resistance to Finasteride in BPH patients.
research Finasteride
Finasteride can cause lasting erectile dysfunction, low libido, and depression in some patients.
research Advancements in Drug Repurposing: Examples in Psychiatric Medications
Old psychiatric drugs are increasingly being used for new purposes, and technologies like SmartCube® help create new drugs.
research Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.
research A New Look at the 5?-Reductase Inhibitor Finasteride
Finasteride treats enlarged prostate and hair loss, but may cause side effects in some patients.
research Treatment of male rats with finasteride, an inhibitor of 5alpha-reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition
Finasteride treatment in male rats causes long-lasting effects on depression-like behavior, brain cell growth, inflammation, and gut bacteria composition.
research Finasteride, a 5alpha-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice.
Finasteride, a drug, can block the seizure-preventing effects of a hormone called progesterone in mice.
research Tratamientos fitoterapeúticos para la hipertrofia benigna de próstata: serenoa repens
Serenoa repens may help with prostate issues, but more research is needed to confirm its effectiveness.
research 5α-reductase inhibitors/finasteride
Finasteride is a safe and effective long-term treatment for prostate enlargement, reducing prostate volume and related symptoms.
research Risk of estrogen-driven malignancies in females on 5-alpha reductase inhibitors
research Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis
Isotretinoin therapy for acne can cause many reversible side effects, mainly mild skin conditions, and patient understanding of these effects can improve treatment adherence.
research Finasteride Use Does Not Lead to Depression or Suicide: Insights From a Large‐Scale Cohort Study and Mendelian Randomization Analysis
Finasteride does not increase the risk of depression or suicide.
research Risk of rhabdomyolysis from 5-α reductase inhibitors
Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.